Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
Chu
Edward
E
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D007150:Immunohistochemistry; D000077146:Irinotecan; D009154:Mutation; D000077544:Panitumumab; D011518:Proto-Oncogene Proteins / Q000235:genetics; D018631:ras Proteins / Q000235:genetics
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; D000077544:Panitumumab; D000077146:Irinotecan; D066246:ErbB Receptors; D018631:ras Proteins; D000068818:Cetuximab; D002166:Camptothecin